A 2-step decision analytic model consisting of a decision tree-informed Markov structure was used to estimate lifetime outcomes in older patients with prostate cancer. The P-score reclassifies a ...

We constructed a three-state Markov model to estimate costs, quality-adjusted life-years (QALYs), incremental net monetary benefit (INMB), and incremental cost-effectiveness ratios (ICERs) in patients ...

Earlier initiation of digital screening mammography at age 40 years leads to substantial healthcare savings by reducing the cost of breast cancer treatment, according to a new cost-effectiveness study ...

Analysis reveals initiating anal cancer screening at age 35 years or older among men who have sex with men (MSM) with HIV is cost-effective. A greater value was seen if screening was started at 35 ...

A large US study showed population-based multigene testing might be a cost-effective way to identify women at risk for breast and ovarian cancer, potentially preventing more cases but raising concerns ...

Briggs AH, O’Brien BJ, Blackhouse G. 2002. Thinking outside the box: Recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 23:377–401.

A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...

Investigators sought to determine whether a ctDNA-guided adjuvant atezolizumab dosing strategy was more cost-effective than a standard stage-based strategy for patients with MIBC.

Gardasil 4 is the most cost-effective HPV vaccine for women with HIV aged 18-45, reducing cervical cancer and genital warts significantly. ART adherence enhances the cost-effectiveness of HPV ...

Cancer screening is key to saving patients' lives since an earlier stage diagnosis improves survival rates, decreases morbidity, and leads to less intensive treatments. Early detection also has the ...